Thermo Fisher Live Event Shorts

  1. Addressing Post-Translational Modifications In Novel Protein Therapeutics 9/13/2024

    Meinhard Hasslacher, Ph.D., Head of CMC at SOTIO Biotech, addresses an audience question on conjugation efficiencies in this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics. From there, we move on to an audience-led discussion on when to initially address titer, PTMS, and product quality during development of novel protein therapeutic cell lines, with Lena Tholen, Ph.D, Director of Cell Line and Bioprocess Development at FyoniBio and Neeraj Pakala, Ph.D. SVP of Product Development and Manufacturing at Vera Therapeutics weighing in.

  2. Key Attributes To Monitor During Cell Line Development Of Complex Proteins 9/13/2024

    In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, panelists discuss key attributes to monitor during cell line development processes.

  3. Cell Line Selection In Novel Protein Therapeutic Development 9/13/2024

    Lena Tholen, Ph.D., and Meinhard Hasslacher, Ph.D., weigh in early on important cell line selection considerations for novel protein therapeutics in this segment of "Early Process Considerations For Novel Protein Therapeutics".

  4. Three Novel Protein Therapeutic Worldviews 9/13/2024

    In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, we meet panelists who share their topline perspectives on developing complex, novel protein therapeutics.

  5. What's Next For Bioprocess Intensification? 8/27/2024

    Experts speaking on Bioprocess Intensification In The Real World wrap up the Bioprocess Online Live event with parting shots and reflections on the current state of process intensification and what the future holds.

  6. Considerations In Continuous Chromatography 8/27/2024

    In this segment of the Bioprocess Online Live event Bioprocess Intensification In The Real World, our presenters discuss considerations for continuous versus batch chromatography and compare notes on the approaches at their respective organizations.

  7. What Analytics Drive Process Intensification? 8/27/2024

    Bioprocess Online Live panelists discuss the most fundamental analytics that inform and enable process intensification strategies in this segment of Bioprocess Intensification In The Real World.

  8. Process Intensification Development Challenges At AZ and AbbVie 8/27/2024

    In this segment of the Bioprocess Online Live event Bioprocess Intensification In The Real World, panelists respond to audience questions about the challenges they’ve encountered while developing process intensification strategies.

  9. Process Intensification Audience Q&A 8/27/2024

    Our panelists take audience questions on process intensification lessons learned from other industries.

  10. Where Process Intensification Sits In The AbbVie, AstraZeneca Organizations 8/27/2024

    In this segment of the Bioprocess Online Live event Bioprocess Intensification In The Real World, panelists discuss where and how their roles in setting the course for process intensification sit within their greater organizations.